| Dr Michael G Genovesi, MD | |
|
300 Kensington Ave, New Britain, CT 06051-3916 | |
| (860) 224-6266 | |
| (860) 224-6269 |
| Full Name | Dr Michael G Genovesi |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Pulmonary Disease |
| Location | 300 Kensington Ave, New Britain, Connecticut |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013913995 | NPI | - | NPPES |
| 912409 | Other | CT | HEALTH NET REF ID |
| 004062394 | Medicaid | CT | |
| 010018248CT01 | Other | CT | BCBS N BCFP PROV ID |
| 059108-1631 | Other | CT | CONNECTICARE ID |
| 001182484 | Medicaid | CT | |
| 01018248 | Other | CT | CIGNA PROV ID |
| 060028 | Other | CT | HEALTH NET PROV ID |
| 135689 | Other | CT | WELLCARE MEDICARE |
| 476841 | Other | CT | AETNA REF ID |
| P369819 | Other | CT | OXFORD ID |
| 1255448155 | Other | CT | GHMC GRP NPI ID |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | 18248 (Connecticut) | Primary |
| Entity Name | Starling Physicians, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467537290 PECOS PAC ID: 7517863749 Enrollment ID: O20031209000877 |
News Archive
Most people don't know much about clinical trials, according to surveys across all races and groups. Yet many members of the Hispanic community fear and distrust doctors, hospitals, and medical research. Part of this distrust may have come from the legacy of enforced sterilizations that Latinas experienced before World War II in Puerto Rico.
At a press conference held in Coral Gables September 1st, 2009, Centro Mater Foundation's president, Ana Ortega, announced details of the organization's alliance with Navarro Discount Pharmacies.
An analysis of a large nationally representative longitudinal study by University of California San Diego Herbert Wertheim School of Public Health and Human Longevity Science report that starting tobacco products, including e-cigarettes, before the age of 18 is a major risk factor for people becoming daily cigarette smokers.
Critical Path Institute (C-Path) and the Innovative Medicines Initiative (IMI) announced today that they have signed a Memorandum of Understanding (MoU) to further the missions of both organizations.
GlaxoSmithKline (GSK) and Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc. (Impax), today announced an agreement for the development and commercialization of IPX066, Impax's novel extended release carbidopa-levodopa product, outside the United States and Taiwan. IPX066, an investigational product under development for the treatment of Parkinson's Disease (PD), is currently in Phase III clinical trials.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael G Genovesi, MD 300 Kensington Ave, New Britain, CT 06051-3916 Ph: (860) 224-6266 | Dr Michael G Genovesi, MD 300 Kensington Ave, New Britain, CT 06051-3916 Ph: (860) 224-6266 |
News Archive
Most people don't know much about clinical trials, according to surveys across all races and groups. Yet many members of the Hispanic community fear and distrust doctors, hospitals, and medical research. Part of this distrust may have come from the legacy of enforced sterilizations that Latinas experienced before World War II in Puerto Rico.
At a press conference held in Coral Gables September 1st, 2009, Centro Mater Foundation's president, Ana Ortega, announced details of the organization's alliance with Navarro Discount Pharmacies.
An analysis of a large nationally representative longitudinal study by University of California San Diego Herbert Wertheim School of Public Health and Human Longevity Science report that starting tobacco products, including e-cigarettes, before the age of 18 is a major risk factor for people becoming daily cigarette smokers.
Critical Path Institute (C-Path) and the Innovative Medicines Initiative (IMI) announced today that they have signed a Memorandum of Understanding (MoU) to further the missions of both organizations.
GlaxoSmithKline (GSK) and Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc. (Impax), today announced an agreement for the development and commercialization of IPX066, Impax's novel extended release carbidopa-levodopa product, outside the United States and Taiwan. IPX066, an investigational product under development for the treatment of Parkinson's Disease (PD), is currently in Phase III clinical trials.
› Verified 3 days ago
Brenda Nurse, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 2150 Corbin Ave, New Britain, CT 06053 Phone: 860-832-6248 | |
Dr. Yousong Wang, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 300 Kensington Ave, New Britain, CT 06051 Phone: 860-612-0485 | |
Justin B Lundbye, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 100 Grand St, Cardiology Department, New Britain, CT 06052 Phone: 860-224-5731 Fax: 860-224-5749 | |
Rekha Kumari, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 100 Grand St, New Britain, CT 06052 Phone: 860-224-5990 Fax: 860-972-7040 | |
Dr. Manmeet Kaur, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 100 Grand St, Joslin Diabetes Center, New Britain, CT 06052 Phone: 860-224-5672 | |
Dr. Ujwol Karmacharya, MD Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 100 Grand Street, New Britain, CT 06052 Phone: 860-224-5011 |